Zacks Small-Cap Research has initiated coverage of Cosmos Health Inc., assigning the company a $4.50 per share valuation. The report, authored by analyst Brad Sorensen, highlights Cosmos Health's diversified revenue base, vertically integrated pharmaceutical and manufacturing operations, expansion into the U.S. market, and improving financial performance as key factors supporting its outlook. The valuation is based on a five-year discounted cash flow analysis, reflecting projected revenue growth, improving gross margins, and a transition toward positive free cash flow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9625758) on January 14, 2026, and is solely responsible for the information contained therein.